Go online to PeerView.com/HPR860 to view the entire program with slides. In this activity, an expert in B-cell lymphoma discusses updated efficacy and safety evidence on several new agent classes across a range of lymphoma settings, including B-cell receptor inhibitors, novel antibodies, Bcl-2 inhibitors, immunomodulators, and CAR-T therapy. In addition, this activity explores the role of these various therapeutic options in diseases such as FL, CLL, MCL, and DLBCL, and also reviews important safety and dosing information useful for clinical care. Upon completion of this activity, participants will be able to: Summarize updated efficacy and safety evidence on BCR inhibitors, apoptosis agents, next-generation antibodies, immunomodulators, CAR-T cell therapy, and other emerging strategies in different B-cell lymphoma settings, Employ regimens with novel components for the management of newly diagnosed or relapsed/refractory indolent and aggressive lymphoma, including diseases such as CLL, FL, MCL, or DLBCL, among others, Manage safety considerations in patients with B-cell malignancies who are receiving treatment with novel agent classes

Go online to PeerView.com/CBT860 to view the entire program with slides. In this activity, experts in oncology and emergency medicine discuss principles of using immunotherapy to treat cancer, focusing specifically on the development of and recommendations for identifying, grading, and managing IMARs. Upon completion of this activity, participants will be able to: Describe the basic principles of harnessing the human immune system in the treatment of cancer, including the mechanistic aspects of immune checkpoint inhibition and development of immune-mediated adverse reactions (IMARs), Characterize the spectrum of IMARs: organ systems potentially impacted, presenting symptoms, and timing of occurrence, Discuss the general and organ-specific recommendations for evaluation, grading, and management of IMARs, including specific considerations for emergency care settings, Implement recommended strategies for triage and management of IMARs in the emergency care setting, Coordinate assessment and transition of care of patients experiencing IMARs with oncologists and medical subspecialists

Breaking the Paradox: Expanding Options and New Questions in HCC Management—Mapping the Pathways to Better Patient Outcomes

The TRK to Tumor-Agnostic Care in Solid Tumors: A Pathology-Focused Guide to the Clinical Role of TRK Fusions in Personalizing Cancer Therapy

Defining the Role of Extended Half-Life Replacement Clotting Factors in the Modern Management of Hemophilia A

Beyond Clinical Trials: Can Real-World Evidence Provide a Roadmap for Long-Term Treatment Planning in EGFRMutation-Positive NSCLC?

Molecular Testing for EGFR Mutations in the Context of a Changing Treatment Landscape, Evolving Testing Options, and Updated Guidelines: What Pathologists Need to Know and Do

Keeping Pace With Immunotherapy Advances in Bladder Cancer: Tools for Winning the Race and Optimizing Patient Outcomes

Progress in Developing Novel Treatment Options for PTCL: Expert Views on Integrating Innovative Therapeutics Into Care

The Central Role of Biomarker Testing in Piecing Together the Immuno-Oncology Puzzle: Essential Guidance for Pathologists to Maximize the Potential of Cancer Immunotherapies